Market Research on Anti-Infective Vaccines Market 2016 and Analysis to 2026

Rapidly spreading infectious diseases such as tuberculosis, malaria, Hepatitis B, HIV/AIDS, influenza and others are becoming major concern to the society and the healthcare professionals as they are majorly contributing to worldwide causes of death and presenting huge burden on healthcare systems. Infectious diseases are treated with category of drugs including antivirals and anti-infective agents along with adjunct therapy of immune system boosters. Anti-infective vaccines are the most powerful health measure taken by the healthcare systems to prevent the rapidly spreading infectious diseases. Infectious diseases being a substantial health threat, numerous companies are trying to innovate novel anti-infective vaccines to combat patient burden on medical managements. Anti-infective vaccines for the prophylaxis of diseases such as influenza (Fluarix, Fluzone, FluMist), hepatitis (Recombivax HB, Havrix, Engerix-B), malaria (RTS, S), polio (IPOL), tuberculosis (BCG) are readily available in market. Anti- infective vaccines for some infectious diseases such as polio and tetanus are given to child after birth under the national immunizatiaon programs.

Anti-infective vaccines Market: Drivers and Restraints

Increasing incidence of infectious diseases, incidence of new emerging diseases, bioterrorism and resistance to existing anti-infective therapies are the major drivers for the growth of global anti-infective vaccines market. Moreover, growing awareness for infectious disease diagnosis, increasing health consciousness, advancements in medical technology, thriving demands for control on infectious diseases are some other factors expected to flourish the growth of global anti-infective vaccines market. However, unavailability of anti-infective vaccines in some underdeveloped regions and high prizes of immunization can be the hurdles in the growth of global anti-infective vaccines market.

Request Free Report Sample@...